Pharming Group cuts 2026 revenue guidance by $30m on weak sales By Investing.com
Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.
How this was made
The 30-second read
Why it matters
The guidance reduction is tied to Ruconest sales decline and channel actions (inventory drawdowns and withdrawals), while management expects stabilization and growth in H2 supported by rising patient enrollments.
Market read
A concrete 2026 revenue guidance cut plus Q2 miss versus consensus provides a fresh catalyst for repricing PHAR’s forward revenue and margin expectations.
What to watch
The article cites inventory drawdowns and planned withdrawals outside the US as contributors to the shortfall; traders may separate temporary channel effects from underlying demand trends.
Background
Pharming reported Q2 results with continued weakness in its legacy Ruconest product and adjusted 2026 revenue expectations accordingly.
Ticker impact
Pharming cut 2026 revenue guidance by $30m to $375m-$395m after Q2 sales missed expectations, driven by weaker Ruconest demand.
Near-term bearish bias as traders reprice 2026 expectations; upside depends on management’s stated H2 Ruconest stabilization and enrollment trend.
The article provides a concrete guidance reduction, Q2 revenue and Ruconest sales misses versus consensus, and a specific product-level driver (legacy Ruconest weakness).
Market effects
Highlights ongoing pressure on legacy rare-disease products and the market’s sensitivity to revenue guidance revisions.
Primarily impacts US-listed biotech sentiment; no direct regional macro linkage beyond US market dynamics cited for Ruconest.
Guidance cut may affect global rare-disease peers’ read-across on legacy product trajectories, but impact is company-specific.
Counterpoint
The company lowered revenue guidance but also reduced operating expense guidance, which could partially offset margin pressure if Ruconest stabilizes in H2 as enrollment improves.
Key entities
- companyPharming Group
Cut 2026 revenue guidance by $30m to $375m-$395m after Q2 sales missed consensus, driven by weaker Ruconest demand.
- productRuconest
Legacy product with Q2 sales down 10% YoY to $72.3m, missing consensus; management expects decline to moderate in 2026 and stabilize in H2.
- productJoenja
Q2 revenues $17.9m, slightly above consensus, with new US patient additions.
